We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Metabolomic Study Reveals Early Diagnostic Marker for Type II Diabetes

By LabMedica International staff writers
Posted on 30 Sep 2013
The metabolite 2-aminoadipic acid (2-AAA) has been identified as a biomarker that can predict risk of developing type II diabetes up to 10 years before onset of the disease.

Investigators at Vanderbilt University (Nashville, TN, USA) and their colleagues at Harvard Medical School (Boston, MA, USA) employed a liquid chromatography–tandem mass spectrometry (LC-MS/MS) metabolomics platform that analyzed intermediary organic acids, purines, pyrimidines, and other compounds. More...
Metabolomics is the study of chemical processes involving metabolites, while the metabolome represents the collection of all metabolites in a biological cell, tissue, organ, or organism that are the end products of cellular processes.

For this study, the investigators performed a nested case-control study of 188 individuals who developed type II diabetes and 188 matched controls from a group of 2,422 nondiabetic participants followed for 12 years in the Framingham Heart Study.

Results revealed that 2-AAA was the metabolite most strongly associated with the risk of developing type II diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a four-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct physiological pathway.

In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Furthermore, 2-AAA treatment enhanced insulin secretion from a pancreatic beta-cell line as well as murine and human islets.

“From the baseline blood samples, we identified a novel biomarker, 2-aminoadipic acid (2-AAA) that was higher in people who went on to develop diabetes than in those who did not,” said first author Dr. Thomas J. Wang, professor of cardiology at Vanderbilt University. “That information was above and beyond knowing their blood sugar at baseline, knowing whether they were obese, or had other characteristics that put them at risk. 2-AAA appears to be more than a passive marker. It actually seems to play a role in glucose metabolism. It is still a bit early to understand the biological implications of that role, but these experimental data are intriguing in that this molecule could be contributing in some manner to the development of the disease itself.”

“Diabetes is common and the prevalence will only rise in coming years fueled by the rise of obesity. Understanding why diabetes occurs and how it might be prevented is a very intense area of investigation because of the serious consequences of having the disease,” said Dr. Wang. “It is certainly a focus of many research groups to understand how we might develop strategies to detect diabetes risk at an earlier stage and intervene.”

The study was published in the September 16, 2013, online edition of the Journal of Clinical Investigation.

Related Links:
Vanderbilt University
Harvard Medical School



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.